MedTrace Logo

Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab

NCT04200833 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2022-05-05

Study results available
· View outcomes & findings →

Summary

To asses the use of golimumab, a fully humanized anti-TNF Alpha monoclonal antibody, in juvenile idiopathic Arthritis-associated uveitis refractory to adalimumab.

Conditions

  • JIA Associated Uveitis

Interventions

DRUG

Golimumab

subcutaneous injection

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-01
Primary Completion
2021-07-01
Completion
2021-08-01
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04200833 on ClinicalTrials.gov